Neurology News and Research

Latest Neurology News and Research

Children suffering from chronic headache may outgrow the condition

Most children who suffer from chronic daily headache may outgrow the disabling condition, according to research published in the July 15, 2009, online issue of NeurologyÂ®, the medical journal of the American Academy of Neurology. Nearly 1.5 percent of middle school children are affected by chronic daily headache, which includes chronic migraines and tension-type headaches.

1 Sep 2009

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

While smoking cigarettes appears to significantly increase a person's risk of developing multiple sclerosis, using Swedish snuff does not, according to a study published in the September 1, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Sep 2009

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).

1 Sep 2009

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

1 Sep 2009

Cannasat Therapeutics announces completion of second tranche of prospectus offering

Cannasat Therapeutics Inc. ("Cannasat") (TSX VENTURE:CTH) is pleased to announce that it has completed a second tranche of its previously announced short form prospectus offering of units. Pursuant to the second tranche, Cannasat issued and sold 1,789,000 units at a price of $0.10 per unit raising gross proceeds of $178,900. This brings the total number of units sold under the prospectus offering to 9,298,500 for gross proceeds of $929,850.

1 Sep 2009

VAERS calls for reporting of GBS cases following 2009 H1N1 flu vaccination

The Centers for Disease Control and Prevention (CDC) and the American Academy of Neurology (AAN) are requesting neurologists to report any possible new cases of Guillain-Barr- syndrome (GBS) following 2009 H1N1 flu vaccination using the CDC and U. S. Food and Drug Administration Vaccine Adverse Event Reporting System (VAERS).

1 Sep 2009

AAO-HNSF to issue the first guideline for helping physicians manage dysphonia

The American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) will issue the first--and only--national clinical practice guideline to help healthcare practitioners identify and manage patients with hoarseness, also known as dysphonia. The guideline emphasizes evidence-based management of hoarseness by clinicians, and educates patients on the prevalence of this common vocal health issue.

1 Sep 2009

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.

31 Aug 2009

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

31 Aug 2009

HIV subtype D infected patients more likely to develop dementia

Patients infected with a particular subtype of HIV, the virus that causes AIDS, are more likely to develop dementia than patients with other subtypes, a study led by Johns Hopkins researchers shows. The finding, reported in the September Clinical Infectious Diseases, is the first to demonstrate that the specific type of HIV has any effect on cognitive impairment, one of the most common complications of uncontrolled HIV infection.

28 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

Ipsen Group announces first-half 2009 financial results

The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group’s results for the first half 2009, published today. The full 2009 half year financial report is available on the Group’s web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.

28 Aug 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

Sabril (vigabatrin) Oral Solution receives approval from FDA

Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to 2 years. Sabril is the first drug in the United States approved to treat the disorder, characterized by a severe type of seizure that usually appears in the first year of life, typically between ages 4 months and 8 months.

26 Aug 2009

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

Obesity is on a rampage, with the World Health Organization pegging the numbers at more than 300 million worldwide, with a billion more overweight. With obesity comes the increased risk for cardiovascular disease, Type II diabetes, and hypertension.

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Emdeon and BroMenn Healthcare System implement an interactive software application for transparent pricing of healthcare

Emdeon, a leading provider of revenue and payment cycle management solutions for the healthcare industry, and BroMenn Healthcare System, headquartered in Bloomington-Normal, Illinois, recently implemented the Emdeon Patient Responsibility Estimator(SM) solution. Emdeon Patient Responsibility Estimator is an interactive software application used by BroMenn's patient access staff to inform patients of their financial responsibility prior to care delivery.

25 Aug 2009

People with high diastolic blood pressure more likely to have cognitive impairment

High blood pressure is linked to memory problems in people over 45, according to research published in the August 25, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

24 Aug 2009

Neurology News and Research

Latest Neurology News and Research

Children suffering from chronic headache may outgrow the condition

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics announces completion of second tranche of prospectus offering

VAERS calls for reporting of GBS cases following 2009 H1N1 flu vaccination

AAO-HNSF to issue the first guideline for helping physicians manage dysphonia

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

HIV subtype D infected patients more likely to develop dementia

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Ipsen Group announces first-half 2009 financial results

Important development in the treatment of multiple sclerosis

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Sabril (vigabatrin) Oral Solution receives approval from FDA

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Emdeon and BroMenn Healthcare System implement an interactive software application for transparent pricing of healthcare

People with high diastolic blood pressure more likely to have cognitive impairment

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Neurology News and Research

Latest Neurology News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in